ReproCELL Incorporated (4978) Q4 2025 earnings summary

Executive summary

• Revenue increased 22.7% year-over-year to 2,978 million yen, with operating loss narrowing to 130 million yen and net income turning positive at 103 million yen from a loss of 31 million yen in the prior year.

• The company operates two main segments: Research Support (short- to mid-term revenue base) and Medical (mid- to long-term growth driver), focusing on iPS cell technology and regenerative medicine.

• Research Support segment saw strong growth in sales and profit, while Medical segment advanced key regenerative medicine pipelines and expanded global manufacturing capabilities.

Financial highlights

• Operating loss improved to 130 million yen from 409 million yen loss year-over-year; ordinary profit rose to 45 million yen, up 12.1%.

• Net income attributable to shareholders was 103 million yen, reversing a prior year loss.

• Cash and equivalents at year-end were 2,823 million yen, down 115 million yen from the previous year.

• No dividends declared; company continues to prioritize R&D investment and financial stability.

Outlook and guidance

• FY2026 forecast: revenue to rise 2.0% to 3,037 million yen, but operating loss expected to widen to 268 million yen and net loss of 75 million yen projected.

• Guidance assumes stable foreign exchange rates and continued investment in R&D and global expansion.